China National Medicines Corporation Ltd. (SHA:600511)
China
· Delayed Price · Currency is CNY 29.76
+0.04 (0.13%)
May 13, 2025, 2:45 PM CST
SHA:600511 Revenue
China National Medicines Corporation had revenue of 12.71B CNY in the quarter ending March 31, 2025, with 4.87% growth. This brings the company's revenue in the last twelve months to 51.19B, up 1.18% year-over-year. In the year 2024, China National Medicines Corporation had annual revenue of 50.60B with 1.81% growth.
Revenue (ttm)
51.19B
Revenue Growth
+1.18%
P/S Ratio
0.44
Revenue / Employee
16.49M
Employees
3,104
Market Cap
22.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 50.60B | 901.40M | 1.81% |
| Dec 31, 2023 | 49.70B | 4.20B | 9.23% |
| Dec 31, 2022 | 45.50B | -970.02M | -2.09% |
| Dec 31, 2021 | 46.47B | 6.09B | 15.08% |
| Dec 31, 2020 | 40.38B | -4.27B | -9.56% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |